# A Superiority Trial of Radiofrequency Ablation for Low Back Pain (ASTRAL)

> **NIH NIH R34** · UNIVERSITY OF WASHINGTON · 2022 · $309,984

## Abstract

Low back pain is the #1 contributor to years lived with disability, driven mainly by chronic low back pain
(CLBP; pain lasting ≥3 months). An obstacle to reducing the societal burden of CLBP is that most treatments
have only small magnitude treatment effects (5-10% improvements in functional limitations and pain).
 Lumbar radiofrequency ablation (LRFA) is a minimally invasive procedure that is widely performed for
CLBP. It can be used in patients for whom CLBP is isolated to the lumbar facet joints, defined by pain relief
(“positive responses”) with local anesthetic medial branch blocks (MBBs) to the medial branch nerves. LRFA
applies a thermal lesion to these nerves, temporarily reducing or eliminating CLBP. Unlike most CLBP
treatments, LRFA can result in large-magnitude improvements in well-selected patients. However, LRFA is
neurodestructive, has potential adverse effects, and there is conflicting evidence regarding its effectiveness.
While some randomized controlled trials (RCTs) and systematic reviews support the effectiveness of LRFA,
multiple RCTs of LRFA show no significant effects, including the largest RCT to date. Experts have noted that
those RCTs showing no effects may be explained by (1) poor LRFA technique insufficient to adequately
lesion the medial branches, and (2) suboptimal clinical selection criteria for identifying LRFA candidates.
 The most stringent evidence-based guidelines for LRFA technique and patient selection are those of the
Spine Intervention Society (SIS). The SIS guidelines mandate various aspects of technique to optimize medial
branch lesioning and consequent improvements in CLBP. They also include stringent clinical screening criteria
for determining appropriate LRFA candidates, such as requiring ≥80% pain improvement to define positive
MBB responses, and 2 separate sets of comparative MBBs with low anesthetic volume (<0.5cc).
 The proposed research will involve the design and planning of a definitive, double-blind multicenter
RCT of LRFA compared to a simulated LRFA control procedure: “A Superiority Trial of Radiofrequency
Ablation for Low Back Pain” (ASTRAL). ASTRAL will adhere to the SIS guidelines, addressing concerns
regarding inadequate LRFA technique and patient selection of past RCTs. The following Aims will be
addressed over a 1.5-year funding period: Aim 1: Finalize the statistical analysis plan (SAP), study protocol,
manual of operations, and data safety monitoring plan (DSMP); Aim 2: Demonstrate that the clinical research
centers (CRCs or “sites”) have sufficient capacity for participation in the future ASTRAL RCT, or identify
alternate sites. Site requirements include sufficient LRFA volume, procedural standards for MBBs and LRFAs,
a research-compatible environment, and mock recruitment; Aim 3: Prepare for centralized randomization, data
collection, and data management; Aim 4. Obtain administrative and regulatory approvals for the future
multicenter ASTRAL RCT; Aim 5: Submit a NIAMS U01 Cooperative...

## Key facts

- **NIH application ID:** 10524686
- **Project number:** 1R34AR080279-01A1
- **Recipient organization:** UNIVERSITY OF WASHINGTON
- **Principal Investigator:** Janna L Friedly
- **Activity code:** R34 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $309,984
- **Award type:** 1
- **Project period:** 2022-08-01 → 2024-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10524686

## Citation

> US National Institutes of Health, RePORTER application 10524686, A Superiority Trial of Radiofrequency Ablation for Low Back Pain (ASTRAL) (1R34AR080279-01A1). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10524686. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*